|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011209,
umls-concept:C0017262,
umls-concept:C0026447,
umls-concept:C0030567,
umls-concept:C0036043,
umls-concept:C0183683,
umls-concept:C0185117,
umls-concept:C0332307,
umls-concept:C0344211,
umls-concept:C0439234,
umls-concept:C0531925,
umls-concept:C0815010,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1520007,
umls-concept:C1521721,
umls-concept:C2911684
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-4-7
|
|
pubmed:abstractText |
Parkinson's disease is characterized by profound motor deficits that result mainly as a consequence of degeneration of midbrain dopaminergic neurons. No current therapy slows or halts disease progression. Neurturin (NTN) and glial cell line-derived neurotrophic factor have potent neuroprotective and neurorestorative effects on dopaminergic neurons, but their use in treating Parkinson's disease has been limited by significant delivery obstacles. In this study, we examined the long-term expression, bioactivity, and safety/tolerability of CERE-120, an adeno-associated virus type 2 vector encoding human NTN, after bilateral stereotactic delivery to the striatum of nonhuman primates.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD68 antigen, human,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitonin Gene-Related Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/Neurturin,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine 3-Monooxygenase,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Matrix Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1524-4040
|
|
pubmed:author |
pubmed-author:BartusRaymond TRT,
pubmed-author:BishopKathie MKM,
pubmed-author:BoltonAriadneA,
pubmed-author:BrownLamarL,
pubmed-author:GammonDawnD,
pubmed-author:GasmiMehdiM,
pubmed-author:HerzogChristopher DCD,
pubmed-author:KordowerJeffrey HJH,
pubmed-author:KruegelBrianB,
pubmed-author:LinRichardR,
pubmed-author:PrintzMarieM,
pubmed-author:WilsonAlistairA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
602-12; discussion 612-3
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19349823-Animals,
pubmed-meshheading:19349823-Antigens, CD,
pubmed-meshheading:19349823-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:19349823-Behavior, Animal,
pubmed-meshheading:19349823-Body Weight,
pubmed-meshheading:19349823-Brain,
pubmed-meshheading:19349823-Calcitonin Gene-Related Peptide,
pubmed-meshheading:19349823-Cell Count,
pubmed-meshheading:19349823-Corpus Striatum,
pubmed-meshheading:19349823-Dependovirus,
pubmed-meshheading:19349823-Dose-Response Relationship, Drug,
pubmed-meshheading:19349823-Eating,
pubmed-meshheading:19349823-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19349823-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:19349823-Gene Expression,
pubmed-meshheading:19349823-Gene Transfer Techniques,
pubmed-meshheading:19349823-Genetic Vectors,
pubmed-meshheading:19349823-Humans,
pubmed-meshheading:19349823-Longitudinal Studies,
pubmed-meshheading:19349823-Macaca mulatta,
pubmed-meshheading:19349823-Neurturin,
pubmed-meshheading:19349823-Parkinson Disease,
pubmed-meshheading:19349823-Spinal Cord,
pubmed-meshheading:19349823-Time Factors,
pubmed-meshheading:19349823-Tissue Distribution,
pubmed-meshheading:19349823-Tyrosine 3-Monooxygenase,
pubmed-meshheading:19349823-Viral Matrix Proteins
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
|
|
pubmed:affiliation |
Ceregene, Inc., San Diego, California, USA.
|
|
pubmed:publicationType |
Journal Article
|
